Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib Combined With Radiotherapy for Oligoprogressive NSCLC
NCT04970693Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04970693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04970693.